This study investigated the protective potential of PHYLN extract loaded into niosomal nanocarriers (PHYLN-NIO) against obesity-induced hepatic steatosis and explored its mechanistic similarity to glucagon-like peptide-1 receptor agonists (GLP-1RAs). This evidence concerns the gene GLP1R and fatty liver disease.